nach oben

Die Ophthalmologie

Erschienen in:

19.11.2020 | Chloroquin | CME

Toxische Retinopathien

verfasst von: Prof. Dr. med. Ulrich Kellner, Simone Kellner, Silke Weinitz, Ghazaleh Farmand

Erschienen in: Die Ophthalmologie | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Toxische Retinopathien werden häufig durch externe Stimulanzien (z. B. Nikotin, Poppers, Methanol), seltener durch unerwünschte Arzneimittelwirkungen (UAW) systemisch (z. B. Hydroxychloroquin, Ethambutol, MEK-, ERK-, FLT3-, Checkpointinhibitoren, Didanosin, Pentosanpolysulfat-Natrium) oder intravitreal eingesetzte Medikamente verursacht. Die klinische Symptomatik von UAW ist oft ähnlich zu retinalen Erkrankungen anderer Ursache, sodass die Erkennung von UAW schwierig sein kann. Klinische Befunde, pathophysiologische Mechanismen und, wenn sinnvoll, Screeningstrategien werden diskutiert. Dabei liegt der Fokus auf der Darstellung in der Kausalität gesicherter UAW bei Medikamenten mit bereits langjähriger Zulassung. Bei neuen Medikamenten werden auch kausal ungesicherte Assoziationen dargestellt, um für die weitere Erkennung von UAW bei diesen Medikamenten zu sensibilisieren.

Nita M, Grybowski A (2017) Smoking and eye pathologies. A systematic review. Part II. Retina diseases, uveitis, optic neuropathies, thyroid-associated orbitopathy. Curr Pharm Des 23:639–654PubMed

Cai X, Chen Y, Yang W et al (2018) The association of smoking and risk of diabetic retinopathy in patients with type 1 and type 2 diabetes: a meta-analysis. Endocrine 62:299–306PubMed

Lee DH, Yi HC, Bae SH et al (2018) Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy. PLoS ONE 13:e202103PubMedPubMedCentral

Chua SYL, Dhillon B, Aslam T et al (2019) Associations with photoreceptor measurers in the UK Biobank. Sci Rep 9:19440PubMedPubMedCentral

Kotwal A, Stan M (2018) Current and future treatments for and Graves’ Disease and Graves’Ophthalmopathy. Horm Metab Res 50:871–886PubMed

Giordano L, Deceglie S, d’Adamo P, Valentino ML (2015) Cigarette toxicity triggers Leber’s hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways. Cell Death Dis 17:e2021

El-Shazly AAE, Farweez YAT, Elzankalony YA et al (2018) Effect of smoking on macular function and structure in active smokers versus passive smokers. Retina 38:1031–1040PubMed

Yuan N, Li J, Tang S et al (2019) Association of secondhand smoking exposure with choroidal thinning in children aged 6 to 8 years. The Hongkong Children Eye Study. JAMA Ophthalmol 137:1–9

Hudalla H, Bruckner T, Pöschl J et al (2020) Maternal smoking as an independent risk factor for the development of severe retinopathy of prematurity in very preterm infants. Eye. https://doi.org/10.1038/s41433-020-0963-4CrossRefPubMedPubMedCentral

10.

Ashina H, Li XQ, Olsen EM et al (2017) Association of maternal smoking during pregnancy and birth weight with retinal nerve fiber thickness in children aged 11 or 12 years: the Copenhagen Child Cohort 2000 Eye Study. JAMA Ophthalmol 135:331–337PubMed

11.

Rewbury R, Hughes E, Purbrick R et al (2017) Poppers: legal highs with questionable contents? A case series of poppers maculopathy. Br J Ophthalmol 101:1530–1153PubMed

12.

Nurieva O, Diblik P, Kuthan P et al (2018) Progressive chronic axonal loss following methanol-induced optic neuropathy: four-year prospective cohort study. Am J Ophthalmol 191:100–115PubMed

13.

Schlote T, Kellner U (2016) Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016. Klin Monbl Augenheilkd 233:203–219PubMed

14.

Tsang SH, Sharma T (2018) Drug-induced retinal toxicity. Adv Exp Med Biol 1085:227–232PubMed

15.

Bourgeois N, Chavant F, Lafay-Chebassier C et al (2016) Drugs and retinal disorders: a case/non-case study in the French pharmacovigilance database. Therapie 71:365–374PubMed

16.

Marmor MF, Kellner U, Lai TY et al (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394PubMed

17.

Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110–116PubMed

18.

Ahn SJ, Joung J, Lim HW, Lee BR (2017) Optical coherence tomography protocols for screening of hydroxychloroquine retinopathy in Asian patients. Am J Ophthalmol 184:11–18PubMed

19.

Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460PubMed

20.

Garrity ST, Jung JY, Zambrowski O et al (2019) Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthalmol 103:1600–1604PubMed

21.

Kellner S, Weinitz S, Farmand G, Kellner U (2014) Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 98:200–206PubMed

22.

Nuzbrokh Y, Jauregui R, Oh JK et al (2020) Presumed chloroquine retinopathy with short-term therapy for glioblastoma multiforme. JAMA Ophthalmol. https://doi.org/10.1001/jamaophthalmol.2020.3251CrossRefPubMed

23.

Nti AA, Serrano LW, Sandhu HS et al (2019) Frequent subclinical macular changes in combined BRAF/MEK inhibition with high-does hydroxychloroquine as treatment for advanced metastatic BRAF mutant melanoma: Preliminary results from a phase I/II clinical treatment trial. Retina 39:502–513PubMedPubMedCentral

24.

DiNicola M, Barteselli G, Dell’Arti L et al (2015) Functional and structural abnormalities in Deferoxamine retinopathy. Biomed Res Int. https://doi.org/10.1155/2015/249617CrossRef

25.

Jain N, Li AL, Yu Y, van der Beek BL (2020) Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol 104:1093–1097PubMed

26.

Vora RA, Patel AP, Melles R (2020) Prevalence of maculopathy associated with long-term pentosan polysulfate therapy. Ophthalmology 127:835–836PubMed

27.

Shah R, Simonett JM, Lyons RJ et al (2020) Disease course in patients with pentosan polysulfate sodium maculopathy after drug cessation. JAMA Ophthalmol 138:894–900PubMedPubMedCentral

28.

Zaugg BE, Bell JE, Taylor KY, Bernstein PS (2017) Ezogabine (Potiga) maculopathy. Retin Cases Brief Rep 11:38–43PubMed

29.

Borovik AM, Bosch MM, Watson SL (2009) Ocular pigmentation associated with clozapine. Med J Aust 190:210–211PubMed

30.

Baba T, Kubota-Taniai M, Kitahashi M et al (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870PubMed

31.

Haug SJ, Wong RW, Day S et al (2016) Didanosine retinal toxicity. Retina 36(Suppl 1):S159–S167PubMed

32.

Sophie R, Moses GM, Hwang ES, Kim JE (2019) Fundus hypopigmentation and loss of choroidal nevi pigmentation associated with Nivolumab. JAMA Ophthalmol 137:851–853PubMed

33.

Gianni L, Panzini I, Li S et al (2006) International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 106:505–513PubMed

34.

Hager T, Seitz B (2013) Ocular side effects of biological agents in oncology: what should the clinician be aware of? Onco Targets Ther 24:69–77

35.

Crisostomo S, Vieira L, Cardigos J et al (2020) Tamoxifen-induced chorioretinal changes: an optical coherence tomography and optical tomography angiography study. Retina 40:1185–1190PubMed

36.

Wieder MS, Harooni M, Rusu I (2019) Association of crystalline retinopathy with anastrozole. JAMA Ophthalmol 137:581–582PubMed

37.

Hueber A, Rosentreter A, Severin M (2011) Canthaxanthion retinopathy: long-term observations. Ophthalmic Res 46:103–106PubMed

38.

Schlote T, Kellner U (2009) Nebenwirkungen von Medikamenten am Auge. Klin Monbl Augenheilkd 226:173–186

39.

Moss HE (2017) Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly and the unknown. Eye Brain 29:13–21

40.

Heath G, Airody A, Gale RP (2017) The ocular manifestations of drugs used to treat Multiple Sclerosis. Drugs 77:303–311PubMed

41.

Chelala E, Arej N, Antoun J et al (2017) Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 62:199–204PubMed

42.

Perez JM, Teo K, Ong R et al (2020) Optical coherence tomography characteristics of taxane-induced macuar edema and other multimodal imaging findings. Graefe Arch. Clin Exp Ophthalmol 258:1607–1615

43.

Hu J, Vu JT, Hong B, Gottlieb C (2020) Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open-angle glaucoma. Br J Ophthalmol 104:1040–1044PubMed

44.

Shin YK, Lee GW, Kang SW et al (2020) Macular abnormalities associated with 5alpha-reductase inhibitor. JAMA Ophthalmol 138:732–739PubMed

45.

Breazzano MP, Coleman DJ, Chen RWS et al (2020) Prospective impact of sildenafil on chronic central serous chorioretinopathy. Ophthalmol Retin. https://doi.org/10.1016/j.oret.2020.06.006CrossRef

46.

Araki T, Ishikawa H, Iawhashi C et al (2019) Central serous chorioretinopathy with and without steroids: a multicenter survey. PLoS ONE 24:e213110

47.

Aronow ME, Adamus G, Abu-Asab M et al (2012) Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature. Surv Ophthalmol 57:558–564PubMedPubMedCentral

48.

Dalvin LA, Jihnson AA, Pulido JS et al (2015) Nonantibestrophin Anti-RPE antibodies in paraneoplastic exudative polymorphous vitelliform maculopathy. Transl Vis Sci Technol 15:4

49.

Van der Noll R, Leijen S, Neuteboom GH et al (2013) Effect of inhibition of the FGFR-MPAK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 39:664–672PubMed

50.

Booth AEC, Hopkins AM, Rowland A (2020) Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy. Ther Adv Med Oncol 12:1–10

51.

Méndez-Martínez S, Calvo P, Ruiz-Moreno O (2019) Ocular adverse events associated with MEK inhibitors. Retina 39:1435–1450PubMed

52.

Lüdeke I, Terheyden P, Grisanti S, Lüke M (2016) Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierenden kutanen Melanoms. Ophthalmologe 113:861–863PubMed

53.

Sandhu HS, Kolomeyer AM, Lau MK et al (2017) Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vermurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep 13:103–107

54.

Sioufi K, Das S, Say EAT (2020) A case of extracellular signal-regulated kinase inhibitor associated retinopathy. JAMA Ophthalmol 138:1002–1004PubMed

55.

Mantopoulus D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133:965–967

56.

Dalvin LA, Shields CL, Orloff M et al (2018) Checkpoint inhibitor immune therapy. Systemic indications and ophthalmic side effects. Retina 38:1063–1078PubMed

57.

Liu Y, Haq Z, Pasricha ND, Beyer GJ (2020) Acute macular neuroretinopathy associated with an oral FLT3 inhibitor. JAMA Ophthalmol. https://doi.org/10.1001/jamaophthalmol.2020.2815CrossRefPubMedPubMedCentral

58.

Salgado JP, Khoramnia R, Maier MM et al (2011) Akute Visusminderung während der Therapie einer chronischen Hepatitis C. Ophthalmologe 108:561–564PubMed

59.

Rentiya ZS, Wells M, Bae J et al (2019) Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 257:447–452PubMed

60.

Lai CH, Yang YH, Chen PC et al (2017) Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study. Pharmacoepidemiol Drug Saf. https://doi.org/10.1002/pds.4363CrossRefPubMed

61.

Kondapalli SSA (2020) Retinal vasculitis after administration of Brolucizumab resulting in severe loss of visual acuity. JAMA Ophthalmol. https://doi.org/10.1001/jamaophthalmol.2020.2810CrossRefPubMed

62.

Baumal CR, Spaide RF, Vajzovic L et al (2020) Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab. Ophthalmology. https://doi.org/10.1016/j.ophtha.2020.04.017CrossRefPubMed

63.

Sun MT, Wood MK, Chan WO et al (2017) Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin. A systematic review and meta-analysis. JAMA Ophthalmol 135:864–870PubMedPubMedCentral

64.

Treder M, Alnawaiseh M, Wirths G et al (2018) Spontane intraokulare Blutungen unter oraler Antikoagulation: Axipaban in Vergleich zu Phenprocoumon. Ophthalmologe 115:573–578PubMed

65.

Uyhazi KE, Miano T, Pan W et al (2018) Association of novel oral antithrombotics with the risk of intraocular bleeding. JAMA Ophthalmol 136:122–130PubMed

66.

Makuloluwa AK, Tiew S, Briggs M (2019) Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye 33:1044–1059PubMedPubMedCentral

67.

Cordero-Coma M, Salazar-Méndez R, Garzo-Garcia I, Yilmaz T (2015) Drug-induced uveitis. Expert Opin Drug Saf 14:111–126PubMed

68.

Agarwal M, Majumder PD, Babu K et al (2020) Drug-induced uveitis: a review. Indian J Ophthalmol 68:1799–1807PubMedPubMedCentral

69.

Keren S, Leibovitch I, Cnaan RB et al (2019) Aminobiphosphonate-associated orbital and ocular inflammatory disease. Acta Ophthalmol 97:e792–e799PubMed

70.

Lee H, Jin Y, Roh M et al (2020) Risk of cataract surgery and age-related macular degeneration after initiation of Denosumab vs Zolderonic acid for osteoporosis: a multi-database cohort study. Drugs Aging 37:311–320PubMed

71.

Padidam S, Burke MT, Apple DB et al (2019) Association of Ledipasvir-Sofosbuvir treatment with uveitis in patients treated for hepatitis C. JAMA Ophthalmol 137:568–570PubMedPubMedCentral

72.

Yang MC, Lin KY (2019) Drug-induced acute angle-closure glaucoma: a review. J Curr Glaucoma Pract 13:104–109PubMedPubMedCentral

73.

Winter G, Schaudig U, Stemplewitz B (2020) Chlortalidon als Ursache eines bilateralen Effusionssyndroms. Ophthalmologe. https://doi.org/10.1007/s00347-020-01091-9CrossRef

74.

Wright T, Kumarappah A, Stavropoulos A et al (2017) Vigabatrin toxicity in infancy is associated with retinal defect in adolescence. Retina 37:858–858PubMed

75.

Witkin AJ, Chang DF, Jumper MJ et al (2017) Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteriistics of 36 eyes. Ophthalmology 124:583–595PubMed

76.

Bowen RC, Zhou AX, Bondalapati S et al (2018) Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and cancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 102:1268–1276PubMed

77.

Penha FM, Rodrigues EB, Furlani BA et al (2011) Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol 7:1021–1034PubMed

78.

Bracha P, Ciulla TA, Baumal CR (2018) Vital dyes in vitreomacular surgery. Ophthalmic Surg Lasers Imaging Retina 49:788–798PubMed

79.

Fine HF, Reshef ER, Prenner JL et al (2019) Clinical fidnings in triamcinolone-associated maculopathy. Retina 39:761–765PubMed

80.

Coco RM, Srivastava GK, André-Iglesias C et al (2019) Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: failure of another indirect cytotoxicity analysis. Br J Ophthalmol 103:49–54PubMed

81.

Chamberlain PD, Sadaka A, Berry S, Lee AG (2017) Ethambutol-optic neuropathy. Curr Opin Ophthalmol 28:545–551PubMed

82.

Mandal S, Saxena R, Dhiman R et al (2020) Prospective study to evakluate incidence and indicators for early detection of ethambutol toxicity. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-316897CrossRefPubMed

83.

Alsheri M, Joury A (2020) Oculr adverse effects of amiodaronea systematic review of case reports. Optom Vis Sci 97:536–542

84.

Sotgiu G, Centis R, D’Ambrosio L et al (2012) Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respi J 40:1430–1442

85.

Jaspard M, Butel N, El Helali N et al (2020) Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France. Emerg Infect Dis 26:1792–1800PubMedPubMedCentral

Titel: Toxische Retinopathien
verfasst von: Prof. Dr. med. Ulrich Kellner
Simone Kellner
Silke Weinitz
Ghazaleh Farmand
Publikationsdatum: 19.11.2020
Verlag: Springer Medizin
Schlagwörter: Chloroquin
Chloroquin
Uveitis
Hydroxychloroquin
Erschienen in: Die Ophthalmologie / Ausgabe 12/2020
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-020-01260-w

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Toxische Retinopathien

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Analyse des Stellenwertes von „eLearning“ in der Augenheilkunde und Evaluierung einer „eLearning-App“

Mikrochirurgische Operationstechniken aus ophthalmopathologischer Sicht

Scedosporium apiospermum – Seltener Erreger einer mykotischen Keratitis

Chorioretinale Falten interessanter Genese

Die Geschichte eines Auges – Untersuchung enukleierter Bulbi

Mikrochirurgische Kürzung des CyPass-Stents

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde